28 related articles for article (PubMed ID: 9740693)
1. Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385).
Leaf AN; Wolf BC; Kirkwood JM; Haselow RE
Med Oncol; 2000 Feb; 17(1):47-51. PubMed ID: 10713660
[TBL] [Abstract][Full Text] [Related]
2. Taxanes: their impact on gynecologic malignancy.
Schwab CL; English DP; Roque DM; Santin AD
Anticancer Drugs; 2014 May; 25(5):522-35. PubMed ID: 24300913
[TBL] [Abstract][Full Text] [Related]
3. A screening of a library of T7 phage-displayed peptide identifies E2F-4 as an etoposide-binding protein.
Takami M; Takakusagi Y; Kuramochi K; Tsukuda S; Aoki S; Morohashi K; Ohta K; Kobayashi S; Sakaguchi K; Sugawara F
Molecules; 2011 May; 16(5):4278-94. PubMed ID: 21610657
[TBL] [Abstract][Full Text] [Related]
4. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
5. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Rose PG; Blessing JA; Soper JT; Barter JF
Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group.
Mannel RS; Blessing JA; Boike G
Gynecol Oncol; 2000 Oct; 79(1):64-6. PubMed ID: 11006033
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Morris M; Blessing JA; Monk BJ; McGehee R; Moore DH
J Clin Oncol; 2004 Aug; 22(16):3340-4. PubMed ID: 15310778
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy for recurrent spinal cord ependymona.
Chamberlain MC
Cancer; 2002 Sep; 95(5):997-1002. PubMed ID: 12209682
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix.
Morris M; Brader KR; Burke TW; Levenback CF; Gershenson DM
Gynecol Oncol; 1998 Aug; 70(2):215-8. PubMed ID: 9740693
[TBL] [Abstract][Full Text] [Related]
10. Oral etoposide for the treatment of recurrent ovarian cancer.
Ozols RF
Drugs; 1999; 58 Suppl 3():43-9. PubMed ID: 10711841
[TBL] [Abstract][Full Text] [Related]
11. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment.
de Jong RS; Mulder NH; Dijksterhuis D; de Vries EG
Anticancer Res; 1995; 15(5B):2319-30. PubMed ID: 8572646
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
